Lunginnov wishes to expand its Life Science Products portfolio

  • Lunginnov develops its own R&D programs to deliver innovative solutions to investigators involved in research on diseases related to endothelial dysfunction.
  • If you have a unique product, we would be very happy to make it available to researchers all around the world through our commercialization platform. We can offer to license your unique product and get royalties coming back to you.
  • Lunginnov also offers a range of services including the production of recombinant proteins, monoclonal antibody production and development of ELISA immunoassays.

Lunginnov wishes to commercialize its diagnostics portfolio

  • In promoting clinical acceptance of the company’s diagnostics portfolio through trials and dialogue with the established and new users;
  • In opening the regulatory sale channels with the established users and new users;
  • In utilizing the complementary situation to enter into partnerships for market acceleration in the interests of everyone involved.

Lunginnov wishes to finance its development

  • Lunginnov distributes to shareholders identifiable information impacting on operations, strategy and results of Lunginnov to ensure price equity of the action and to help ensure good corporate governance.
  • Shareholders may request to receive all important information on the development and growth of Lunginnov.


Any person or investor who wishes to become a shareholder of the company can contact it at This email address is being protected from spambots. You need JavaScript enabled to view it.